Drug InfoNet.com
DrugInfoNet Home Page FAQ Drug Info Disease Info Manufacturer Info Health Care News Health Info Become Panelist Health Care Orgs Medical References Government Sites Hospital Sites Medical Schools
Search
Powered By HealthLine
Special Offers
Health Tools
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today



Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine
 Printer Friendly  Send to a Friend

Latest Research Supports New AIDS Drug


Related Encyclopedia
 border=
Abscess
Actinomycosis
Acute Myeloid Leukemia (Adult)
AIDS and HIV Infection
More...

Related Healthscout Videos
 border=
Controlling Incontinence
Fighting HIV and AIDS: New Research
Boy or Girl? You Decide
More...

Related Animations
 border=
Erectile Dysfunction
Menopause
More...

Related Drug Information
 border=
Abilify
Augmentin
Bactroban Cream
Bactroban Ointment
More...

Related News Articles
 border=
Old, Fat Mice Blamed for Virus Transmission
Teen Birth Rate Up in 26 States in 2006
Early Elective C-Sections Produce Complications
Teens Divulge Risky Behavior on Social Networking Sites
More...


Page:  << Prev | 1 | 2

Between 42 percent and 47 percent of the patients taking maraviroc reached reduced levels of the AIDS virus in their bodies, compared to 17 percent of the placebo group.

"There were no apparent side effects or toxicity differences in patients that got maraviroc vs. placebo," Gulick said. "It looked safe and generally well-tolerated over 48 weeks."

The drug works by preventing the AIDS virus from binding to a receptor on immune cells known as CCR5. Some people are born without the receptor and are naturally resistant to the AIDS virus.

Text Continues Below



There are caveats with maraviroc: Doctors must give a $1,900 test to patients to make sure their strain of HIV would be susceptible to the drug, Gulick said. Also, researchers must follow patients on maraviroc to see if any unusual medical problems affect them over time, he said.

Dr. Barry S. Zingman, medical director of the AIDS Center at Montefiore Medical Center in New York City, and one of the doctors taking part in the study, said he has had good experiences prescribing maraviroc.

However, "many patients who need a new treatment option cannot use it" because they don't have the necessary strain of HIV, said Zingman, who has received research grants to study the drug.

In addition, he said, "there are significant interactions between maraviroc and other medications for HIV infection, making it a bit complicated to prescribe in the combination regimens that are standard around the world."

More information

Visit the U.S. Food and Drug Administration for the list of the latest approved HIV drugs.

Page:  << Prev | 1 | 2

Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 10/1/2008

Related Links
 border=
From Healthscout's partner site on genital herpes, HerpesConnection.com
Learn about genital herpes symptoms
What are herpes treatment options?
Get the details about herpes simplex 1 and 2.





SOURCES: Roy Gulick, M.D., professor, medicine, and director, Cornell HIV Clinical Trials Unit, Weill Cornell Medical College, New York City; Barry S. Zingman, M.D., medical director, AIDS Center at Montefiore Medical Center, and associate professor, clinical medicine, Albert Einstein College of Medicine, New York City; Oct. 2, 2008, New England Journal of Medicine


We comply with the HONcode standard for trustworthy health
information:
verify here.
About The HealthScout Network Contact Us
Copyright © 2001-2009. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service    

FAQ Drug Info Disease Info Manufacturer Info Health Care News Health Info Become Panelist Health Care Orgs Medical References Government Sites Hospital Sites Medical Schools
Contact | Site Map | Search | Disclaimer | Mission Statement

© 1996-2003 DRUG INFONET, Inc. All rights reserved.